Company & Sponsor Intelligence
M.D. Anderson Cancer Center
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting2
Completed0
Countries1
Therapeutic footprint
epilepsyother_psychiatrypain_neuropathy
Indexed studies
NCT05431595Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
epilepsy · United StatesPHASE2, PHASE3
epilepsy · United StatesPHASE2, PHASE3
NCT04135326Transcranial Direct Current Stimulation in Reducing Pain in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy
pain_neuropathy · United StatesEARLY_PHASE1
pain_neuropathy · United StatesEARLY_PHASE1
NCT03743649Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
other_psychiatry · United StatesPHASE2, PHASE3
other_psychiatry · United StatesPHASE2, PHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →